中文名稱:CDC25A抗體 | 英文名稱:Rabbit Polyclonal CDC25A Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 3413 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無(wú) | 靶點(diǎn): CDC25A |
WB | 咨詢技術(shù) | Human,Mouse,Rat |
IF | 咨詢技術(shù) | Human,Mouse,Rat |
IHC | 1/50-1/200 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術(shù) | Human,Mouse,Rat |
Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
Aliases | CDC25A2 |
WB Predicted band size | 59 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Mouse, Rat |
Immunogen | Fusion protein of human CDC25A |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue lysate, Primary antibody: P07179(CDC25A Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds
The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07179(CDC25A Antibody) at dilution 1/75. (Original magnification: ×200)
以下是關(guān)于CDC25A抗體的參考文獻(xiàn)示例(內(nèi)容為虛構(gòu),僅作格式參考):
1. **"CDC25A phosphatase as a biomarker in colorectal cancer: Antibody-based detection and clinical implications"**
*Authors: J. Smith et al.*
摘要:本研究利用特異性CDC25A抗體,通過(guò)免疫組化分析結(jié)直腸癌組織,發(fā)現(xiàn)CDC25A高表達(dá)與患者生存率降低顯著相關(guān),提示其作為預(yù)后標(biāo)志物的潛力。
2. **"Development of a monoclonal antibody targeting CDC25A for cell cycle regulation studies"**
*Authors: L. Chen & M. Tanaka*
摘要:報(bào)道了一種新型抗CDC25A單克隆抗體的開(kāi)發(fā),驗(yàn)證其在Western blot和免疫熒光中的特異性,并用于探究CDC25A在G1/S期檢查點(diǎn)中的功能調(diào)控。
3. **"Ubiquitin-mediated degradation of CDC25A: Insights from siRNA and antibody inhibition experiments"**
*Authors: R. Gupta et al.*
摘要:結(jié)合RNA干擾和CDC25A抗體阻斷實(shí)驗(yàn),揭示了泛素-蛋白酶體系統(tǒng)對(duì)CDC25A的降解機(jī)制,闡明其在DNA損傷應(yīng)答中的動(dòng)態(tài)調(diào)控。
4. **"CDC25A overexpression in triple-negative breast cancer: Therapeutic target validation via neutralizing antibodies"**
*Authors: E. Martínez et al.*
摘要:通過(guò)中和性CDC25A抗體抑制乳腺癌細(xì)胞增殖,證實(shí)靶向CDC25A可增強(qiáng)化療敏感性,為三陰性乳腺癌治療提供新策略。
(注:以上文獻(xiàn)及作者為模擬示例,實(shí)際引用請(qǐng)查詢PubMed等數(shù)據(jù)庫(kù)獲取真實(shí)研究。)
CDC25A is a dual-specificity phosphatase belonging to the CDC25 family, which plays a critical role in regulating cell cycle progression. It primarily activates cyclin-dependent kinases (CDKs) by removing inhibitory phosphorylations, thereby driving transitions through the G1/S and G2/M checkpoints. Overexpression or dysregulation of CDC25A is linked to uncontrolled cell proliferation, genomic instability, and tumorigenesis, making it a biomarker of interest in cancers such as breast, lung, and colorectal malignancies.
Antibodies targeting CDC25A are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to quantify protein levels or assess subcellular distribution. High-quality CDC25A antibodies are typically validated for specificity using knockout (KO) cell lines or siRNA-mediated knockdown to minimize cross-reactivity with homologous family members (e.g., CDC25B/C). Species reactivity often includes human, mouse, and rat samples.
In cancer research, CDC25A antibodies help evaluate its prognostic significance and therapeutic potential. Small-molecule inhibitors targeting CDC25A are under investigation, and these antibodies aid in mechanistic studies of drug efficacy. Challenges include distinguishing post-translational modifications (e.g., phosphorylation) that regulate CDC25A stability during DNA damage responses. Researchers must optimize experimental conditions to account for such dynamic changes, ensuring accurate interpretation of CDC25A-related pathways in health and disease.
成立日期 | 2024-06-24 (2年) | 注冊(cè)資本 | 50萬(wàn)(元) |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以內(nèi) |
主營(yíng)行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP5年
|
上海冠導(dǎo)生物工程有限公司
|
2025-08-03 | |
¥1600.00 |
VIP10年
|
北京索萊寶科技有限公司
|
2025-07-30 | |
¥1098 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2025-08-01 | |
詢價(jià) |
VIP1年
|
上海切爾齊生物科技有限公司
|
2025-05-18 |